These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 27163152

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D'Arienzo A, Capanna R, Franchi A.
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
    Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, Deshpande V.
    Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
    [Abstract] [Full Text] [Related]

  • 9. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
    Shibuya I, Takami M, Miyamoto A, Karakawa A, Dezawa A, Nakamura S, Kamijo R.
    Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
    [Abstract] [Full Text] [Related]

  • 10. Denosumab Induces Neoplastic Stromal Cell Apoptosis Via p62 Downregulation Dependent on Autophagy Pathway in Giant Cell Tumour of Bone.
    Chen X, Ye F, He H, Chen G, Chen Z, Ye E, He B, Yang Y, Zhang J.
    Curr Cancer Drug Targets; 2024 Jan; 24(5):565-578. PubMed ID: 37961860
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU, Umer M, Khan Z, Saeed J, Siddiqui MA, Din NU.
    Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H, Ishihara S, Toda Y, Oda Y.
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.
    Wu PF, Tang JY, Li KH.
    Tumour Biol; 2015 Feb; 36(2):495-501. PubMed ID: 25618600
    [Abstract] [Full Text] [Related]

  • 20. Denosumab for the treatment of giant cell tumor of the bone.
    Brodowicz T, Hemetsberger M, Windhager R.
    Future Oncol; 2015 Feb; 11(13):1881-94. PubMed ID: 26161925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.